This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
=== Renewal of diplomatic relations === After the announcement of the release of political prisoners by the Venezuelan government on 8 January, the US and Venezuela began discussions to restart diplomatic relations, including the possibility of reopening the United States embassy in Caracas which was closed in 2019. US officials visited Caracas and on 10 January, the US State Department published a security alert urging its citizens to leave Venezuela immediately due to the presence of colectivos (pro-government paramilitary groups) targeting US citizens. Donald Trump announced on 14 January that he had talked by phone with acting president of Venezuela Delcy Rodríguez on oil, trade and national security. The call was confirmed by Rodríguez, who qualified the phone call as positive. Rodríguez also announced to have sent envoys to meet with United States officials the next day. On 15 January, Central Intelligence Agency (CIA) director John Ratcliffe met with Delcy Rodríguez in Caracas to discuss cooperation and economic stability. According to a US official "The director made clear Venezuela can no longer provide support to drug traffickers like TDA" (referring to the criminal organization Tren de Aragua). After a discussion with Delcy Rodríguez on 29 January, Trump announced the re-opening of Venezuelan airspace. US diplomat Laura Farnsworth Dogu was appointed chargé d'affaires for Venezuela on 22 January, and arrived to Venezuela on 30 January.
=== Industrial radiography === During World War II, Van de Graaff had used the compact generator invented with Trump to detect defects in ship hulls and ordnance for the U.S. Navy. Drawing on this application, HVEC produced 2-MeV industrial X-ray generators for non-destructive testing of manufactured goods. These units, capable of detecting flaws in thick steel sections, weighed more than two tons and were designed to operate in industrial facilities. HVEC adapted these generators to output electron beams, selling a line of industrial radiography equipment and also renting sterilization services to other companies. In 1957, Ethicon, a medical subsidiary of Johnson & Johnson, purchased an HVEC linear accelerator to sterilize surgical sutures, the first commercial medial product to use radiation processing. Sales of e-beam processing machines picked up after HVEC introduced insulating core transformers. ICTs, operating in the lower-voltage 300 keV to 2.5 MeV range, were used for crosslinking polyethylene and other polymers. W. R. Grace's Cryovac division used radiation crosslinking to produce heat-shrinkable materials for food packaging. Other companies purchased ICTs for extended to wire and cable insulation, rubber vulcanization, auto paint, textile modification, and semiconductors.
Tiflorex (TFX), formerly known as flutiorex, is a stimulant amphetamine that was under development as an appetite suppressant in the 1970s, but appears to have been abandoned. It is structurally related to fenfluramine and 4-MTA. Tiflorex went to phase II clinical trials. The extended release formulation "TFX-SR" produced significant suppression of appetite. It also caused slightly more sleep disturbances and headaches than placebo, as well as mydriasis and a self-reported decrease in arousal. It had little effect on heart rate. Tifluorex is claimed to be a more potent anorectic than fenfluramine, with twice its potency in humans and 4 times its potency in rats.
Sources: en.wikipedia.org
== Genetics == Human factor XIII consist of A and B subunits. A subunit gene is F13A1. It is on chromosome 6 at the position 6p24–25. It spans over 160 kbp, has 14 introns and 15 exons. Its mRNA is 3.9 kbp. It has a 5' UTR of 84 bp and a 3' UTR of 1.6 kbp. F13A1 exon(s)
Grapefruit-juice–mediated inhibition of an enzyme that metabolizes the drug to an inactive metabolite leads to excessive levels of the drug in the body. Grapefruit-juice–mediated inhibition either of a membrane transport protein that helps move substances from the intestine to the blood or of an enzyme that converts a prodrug to an active metabolite leads to insufficient levels of the drug in the body resulting in loss of theurapeutic effect. Grapefruit or grapefruit juice can reduce the absorption of many drugs by inhibiting transport across cell membranes by the transporters P-glycoprotein (a member of the superfamily of ATP-binding cassette (ABC) transporters) and members of the organo anion transporter family. These transporters appear to have a minimal effect on systemic exposure of the drugs they affect, however. Many drugs are affected by consumption of citrus juice. When the metabolizing enzyme is inhibited, less of the drug will be metabolized by it in the epithelial cells. This interaction is particularly dangerous when the drug in question has a low therapeutic index, so that a small increase in blood concentration can be the difference between therapeutic effect and toxicity. Citrus juice inhibits the enzyme only within the intestines if consumed in small amounts. When larger amounts are consumed they may in addition inhibit the enzyme in the liver. The hepatic enzyme inhibition may cause an additional increase in potency and a prolonged metabolic half-life (prolonged metabolic half-life for all ways of drug administration).
Tertiary structure refers to the three-dimensional structure created by a single protein molecule (a single polypeptide chain). It may include one or several domains. The α-helices and β-pleated-sheets are folded into a compact globular structure. The folding is driven by the non-specific hydrophobic interactions, the burial of hydrophobic residues from water, but the structure is stable only when the parts of a protein domain are locked into place by specific tertiary interactions, such as salt bridges, hydrogen bonds, and the tight packing of side chains and disulfide bonds. The disulfide bonds are extremely rare in cytosolic proteins, since the cytosol (intracellular fluid) is generally a reducing environment.
== Checkups == Although the symptoms of diabetes mellitus such as frequent urination, thirstiness, greater appetites and inactiveness are easily visible, frequent checking of the dog for the disease is required. The dog's body weight should be determined and calculated once every two weeks using weight scale. The daily caloric requirement by the dog's body and BCS should also be determined using a scale as part of dietary management in maintaining average body weight. The protein intake by the dog should also be considered and checked twice a month. Blood pressure of the dog should also be constantly and daily checked in order to predict any future occurrence. The blood sugar level may also be checked using glucometer to check the glucose level in the body of the dog.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.